Recurrent Erythema Nodosum (Investigational Adjunct)
Investigational adjunct for recurrent idiopathic erythema nodosum; identification and treatment of underlying cause, NSAIDs, potassium iodide, and (refractory) colchicine remain evidence-based.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for erythema nodosum. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for recurrent erythema nodosum is investigational.
- What evidence exists?
- Tier C (investigational). Only anecdotal mention; there are no randomized controlled trials. Evidence-based management of erythema nodosum: identify and treat the underlying cause (streptococcal infection, sarcoidosis, inflammatory bowel disease, tuberculosis, medications, pregnancy), bed rest with leg elevation, NSAIDs, potassium iodide, and colchicine for refractory cases. Most acute cases resolve within 3-6 weeks.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of tender nodular inflammation
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Trigger of new erythema nodosum lesions at bite locations
- Risk in patients with underlying tuberculosis or active sarcoidosis
- Permanent small scars on the shins (typical erythema nodosum site)
- Delay of underlying-cause workup (sarcoidosis, IBD, streptococcal infection)
- Who should not consider this
- Patients without a workup for underlying cause (sarcoidosis, IBD, infection, medications)
- Patients with active tuberculosis or sarcoidosis without specialty management
- Patients with active streptococcal infection (treat the infection first)
- Pregnant patients (pregnancy is a common erythema nodosum trigger)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Patients with peripheral arterial disease of the lower extremities
- What to ask your clinician
- Have I been worked up for sarcoidosis (chest X-ray, ACE level)?
- Have I been tested for tuberculosis and streptococcal infection?
- Could inflammatory bowel disease, medications, or pregnancy be the trigger?
- Have I tried bed rest, leg elevation, and NSAIDs?
- Am I a candidate for potassium iodide or colchicine?
- What evidence specifically supports leech therapy for erythema nodosum?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- New cough, shortness of breath, or chest pain (possible sarcoidosis or tuberculosis)
- New abdominal pain, diarrhea, or rectal bleeding (possible inflammatory bowel disease)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for erythema nodosum.
- Anecdotal mention does NOT establish efficacy versus NSAIDs, potassium iodide, or treating the underlying cause.
- It does NOT replace a workup for sarcoidosis, IBD, infection, or medication triggers.
- It does NOT substitute for bed rest and leg elevation, which are foundational management.
- It does NOT mean leech application is safe on actively inflamed nodular lesions.
Safety cross-references
Clinical Profile
- Category
- dermatological
- ICD-10
- L52
- Safety tier
- medium
Evidence Summary
Erythema nodosum is a septal panniculitis producing painful erythematous nodules on the pretibial surfaces, typically in young women. Always investigate for an underlying trigger: streptococcal infection, sarcoidosis, inflammatory bowel disease, tuberculosis, certain drugs (oral contraceptives, sulfonamides), pregnancy, or malignancy. Many cases are idiopathic. Evidence-based management is treatment of the underlying cause when identified, plus symptomatic NSAIDs, leg elevation, compression, and potassium iodide or colchicine for refractory cases. No published controlled trials of hirudotherapy exist for erythema nodosum. Direct placement on inflamed nodules is contraindicated; perilesional placement on uninvolved skin has been mentioned anecdotally in central European literature without efficacy data.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Placement directly on inflamed nodule (absolute)
- Active untreated underlying cause (streptococcal infection, TB, sarcoidosis, IBD)
- Pregnancy (a common trigger of erythema nodosum)
- Concurrent oral isotretinoin therapy
Related Conditions
Livedo Reticularis
Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.
Lipodermatosclerosis
Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.
Insulin Injection Lipohypertrophy
Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.
Androgenic Alopecia
Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.